CV SCIENCES, INC.

CVSI

CIK 0001510964 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$3M
↓-14.9% -$577Kvs FY2024 (Q4)
Gross Profit
$2M
↓-0.4% -$6Kvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Average
45/100
  • Profitability
    0ROIC -15.1% (10% = solid, 20%+ = moat)
  • Liquidity
    26Current Ratio 1.03 (above 1.5 = solid)
  • Leverage
    44D/E 1.12 (under 0.5 = conservative)
  • Efficiency
    100Asset Turnover 1.85x (1.0+ = capital-efficient)
  • Growth
    0Revenue YoY -14.9% (10% = solid, 25%+ = elite)
  • Margin Trend
    100Op Margin -8.4% · trend +9.1pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$109K
investment in PP&E
Stock-based comp (TTM)
$497K
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$7M
everything owned
Total liabilities
$5M
everything owed
Stockholders' equity
$1M
shareholder claim
Net debt
$1M
LT debt minus cash

Recent performance · 60 quarters

Revenue↓-14.9% -$577K
$3M
Net Income↑+16.2% +$74K
$-382K
Free Cash Flow↑+50.0% +$9K
$-9K
Operating Margin↑+0.4pts
-8.4%

Drill down